investig
dynam
viral
rna
igm
igg
relationship
patient
pneumonia
period
retrospect
observ
case
seri
set
wenzhou
sixth
peopl
hospit
thirtythre
patient
laboratori
confirm
pneumonia
admit
hospit
data
collect
throat
swab
sputum
stool
blood
sampl
collect
viral
load
measur
revers
transcript
pcr
rtpcr
specif
igm
igg
spike
protein
spike
protein
receptor
bind
domain
rbd
nucleocapsid
n
analyz
earli
stage
symptom
onset
viral
load
higher
throat
swab
sputum
lower
stool
median
iqr
time
undetect
viral
rna
throat
swab
sputum
stool
day
day
day
respect
sputum
patient
undetect
viral
rna
within
day
short
persist
persist
viral
rna
day
long
persist
three
patient
detect
relaps
viral
rna
sputum
within
two
week
discharg
hospit
one
patient
persist
viral
rna
day
longer
median
iqr
seroconvers
time
anti
igm
antirbd
igm
antin
igm
day
day
day
respect
median
iqr
seroconvers
time
anti
igg
antirbd
igg
antin
igg
day
day
day
respect
week
symptom
onset
igm
neg
mani
previous
posit
patient
igg
level
remain
less
peak
level
patient
patient
antirbd
igg
level
higher
convalesc
acut
phase
rna
coexist
right
reserv
reus
allow
without
permiss
medrxiv
preprint
antibodi
day
antirbd
igm
igg
level
includ
antirbd
igm
level
present
peak
time
significantli
higher
viral
rna
short
persist
patient
long
persist
patient
studi
add
import
new
inform
featur
viral
load
antibodi
dynam
clear
result
viral
rna
persist
sputum
stool
specimen
rel
long
time
mani
patient
antirbd
may
also
serv
potenti
protect
antibodi
infect
viral
persist
appear
relat
antirbd
level
earlier
treatment
intervent
also
appear
factor
viral
persist
sever
report
serum
antibodi
howev
evalu
diagnost
accuraci
two
articl
report
dynam
viral
rna
antibodi
serial
sampl
observ
period
within
day
none
studi
investig
profil
viral
load
antibodi
long
period
three
report
investig
profil
respiratori
sampl
report
dynam
viral
load
stool
sampl
sputum
stool
rna
persist
long
time
antirbd
antibodi
may
involv
clearanc
infect
eight
week
symptom
onset
igm
neg
mani
previous
posit
patient
igg
level
remain
less
peak
level
patient
patient
antirbd
igg
level
increas
higher
convalesc
acut
phase
long
persist
viral
rna
sputum
stool
present
challeng
manag
infect
igmigg
comb
test
better
singl
igm
test
supplement
diagnost
tool
antirbd
may
protect
antibodi
valuabl
develop
vaccin
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
introduct
novel
coronaviru
sever
acut
respiratori
syndrom
coronaviru
spread
worldwid
april
confirm
case
death
report
clinic
characterist
pneumonia
well
defin
accord
largescal
epidemiolog
studi
china
among
confirm
case
age
year
men
consid
mild
pneumonia
die
common
symptom
includ
fever
cough
fatigu
lymphopenia
etc
admiss
half
patient
present
typic
radiolog
groundglass
opac
chest
comput
tomographi
ct
clearanc
viral
rna
appear
specif
antibodi
essenti
recoveri
viral
infect
viral
load
respiratori
sampl
rapidli
increas
soon
symptom
onset
peak
around
day
convalesc
period
clearanc
viral
rna
patient
stool
delay
compar
oropharyng
swab
recommend
nation
health
commiss
peopl
republ
china
criteria
discharg
hospit
reliev
symptom
two
success
neg
viral
nucleic
acid
result
respiratori
sampl
separ
least
hour
sampl
interv
report
patient
relaps
viral
rna
discharg
hospit
howev
report
includ
four
patient
thu
show
complet
pictur
patient
discharg
hospit
present
report
profil
viral
load
mainli
focus
rel
short
period
less
one
month
longterm
dynam
viral
load
remain
unclear
serolog
respons
patient
essenti
understand
immunolog
mechan
recoveri
process
viral
infect
also
import
develop
serolog
diagnost
tool
sever
assay
develop
detect
specif
igm
igg
studi
focus
either
evalu
detect
method
diagnost
valu
igm
igg
infect
two
studi
investig
dynam
igm
igg
studi
report
median
seroconvers
time
igm
igg
day
respect
patient
earlier
seroconvers
igg
igm
due
lack
serial
result
cohort
patient
longer
period
profil
specif
igm
igg
remain
unclear
antibodi
persist
patient
discharg
hospit
rare
report
though
inform
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
crucial
evalu
immun
profil
recov
patient
thu
relationship
viral
clearanc
serolog
respons
well
investig
studi
investig
profil
viral
rna
igm
igg
group
patient
confirm
pneumonia
period
symptom
onset
baselin
characterist
serial
result
viral
rna
throat
swab
sputum
stool
specimen
monitor
specif
igm
igg
spike
protein
spike
protein
receptor
bind
domain
rbd
nucleocapsid
n
also
measur
way
longterm
relationship
viral
rna
persist
dynam
antibodi
clearli
establish
retrospect
studi
complet
wenzhou
sixth
peopl
hospit
wenzhou
central
hospit
group
one
design
hospit
treat
patient
pneumonia
total
patient
admit
wenzhou
sixth
peopl
hospit
wenzhou
central
hospit
group
januari
februari
includ
studi
among
patient
moder
two
sever
pneumonia
accord
interim
guidanc
issu
nation
health
commiss
peopl
republ
china
patient
follow
day
median
day
discharg
hospit
studi
approv
ethic
commiss
wenzhou
central
hospit
patient
consent
form
sign
patient
team
train
physician
medic
student
review
avail
electron
medic
record
radiolog
find
laboratori
examin
hospit
patient
confirm
infect
data
record
standard
data
collect
form
demograph
data
symptom
onset
time
clinic
featur
radiolog
find
routin
laboratori
result
result
viral
rna
throat
swab
sputum
stool
sampl
record
hospit
followup
result
specif
igm
igg
antibodi
rbd
n
measur
hospit
followup
miss
uncertain
record
clarifi
commun
physician
respons
patient
question
patient
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
continu
variabl
present
median
interquartil
rang
iqr
mean
standard
deviat
sd
categor
variabl
percentag
patient
categori
analyz
differ
patient
sputum
viral
rna
shortpersist
viral
rna
undetect
within
day
longpersist
viral
rna
persist
day
assess
two
sampl
test
wilcoxon
rank
sum
test
depend
parametr
nonparametr
data
continu
variabl
spearman
correl
analysi
use
assess
relationship
paramet
analys
done
spss
version
ibm
armonk
ny
usa
test
twosid
signific
assess
level
funder
role
studi
correspond
author
full
access
data
studi
final
respons
decis
submit
public
total
patient
admit
wenzhou
sixth
peopl
hospit
wenzhou
central
hospit
group
januari
februari
includ
studi
median
age
patient
year
old
rang
less
year
old
among
patient
men
comorbid
ill
supplement
tabl
common
symptom
fever
cough
expector
fatigu
diarrhea
routin
laboratori
paramet
admiss
first
return
visit
time
avail
analysi
laboratori
paramet
admiss
normal
patient
abnorm
paramet
observ
patient
admiss
abnorm
white
blood
cell
count
neutrophil
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
count
lymphocyt
count
platelet
count
creactiv
protein
crp
creatinin
kinas
ck
lactat
dehydrogenas
ldh
blood
urea
nitrogen
bun
blood
creatinin
cr
almost
patient
normal
laboratori
paramet
upon
return
visit
one
week
discharg
supplement
tabl
patient
receiv
antivir
treatment
hospit
atom
interferon
lopinavir
ritonavir
arbidol
ribavirin
lianhuaqingwen
chines
tradit
medicin
use
combin
atom
interferon
use
patient
lopinavir
ritonavir
use
patient
lianhuaqingwen
believ
reliev
fever
cough
use
day
three
patient
show
detect
relaps
viral
rna
sputum
test
two
week
discharg
hospit
one
patient
persist
viral
rna
day
longer
viral
load
first
detect
onset
corel
age
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
figur
compar
igg
level
acut
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
convalesc
phase
increas
observ
patient
anti
patient
antirbd
patient
antin
respect
sinc
detect
rna
sputum
routin
test
treatment
commonli
use
clinic
set
relationship
persist
sputum
viral
rna
antibodi
analyz
figur
compar
viral
rna
long
persist
group
patient
short
persist
group
higher
anti
ig
g
antirbd
igm
antirbd
igg
level
antirbd
igm
level
seroconvers
peak
level
antirbd
igm
also
significantli
higher
short
persist
group
also
observ
time
symptom
onset
hospit
admiss
significantli
differ
short
persist
long
persist
group
investig
serial
viral
load
dynam
antibodi
patient
infect
eightweek
period
follow
onset
symptom
throat
swab
specimen
viral
load
high
begin
infect
declin
quickli
viral
load
stool
sampl
low
initi
period
declin
slowli
sputum
stool
viral
rna
persist
long
time
simultan
seroconvers
igm
igg
observ
patient
igm
peak
fourth
week
except
antin
igm
peak
second
week
igg
peak
fourth
fifth
week
onset
symptom
high
antirbd
antibodi
level
associ
short
persist
rna
sputum
viral
load
vari
across
differ
type
specimen
studi
observ
throat
swab
sampl
viral
load
high
earli
stage
infect
becam
undetect
three
week
follow
symptom
onset
pan
et
al
previous
report
viral
load
sever
type
specimen
two
patient
colleagu
report
viral
load
posterior
oropharyng
saliva
sampl
combin
studi
result
conclud
upper
respiratori
sampl
viral
load
high
shortli
symptom
onset
declin
quickli
detect
rna
respiratori
specimen
includ
guidelin
monitor
treatment
accord
guidelin
patient
discharg
hospit
experienc
relief
symptom
two
success
neg
viral
rna
test
respiratori
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
specimen
across
least
h
sampl
interv
observ
sputum
viral
load
declin
time
patient
undetect
week
onset
symptom
howev
posit
viral
rna
detect
patient
two
week
discharg
hospit
addit
one
patient
cohort
posit
viral
rna
day
symptom
onset
would
go
persist
even
longer
mean
may
persist
long
time
patient
whether
relaps
patient
truli
relaps
result
fals
neg
viral
rna
test
need
explor
studi
also
investig
viral
load
serial
stool
specimen
viral
load
stool
lower
observ
throat
swab
sputum
begin
infect
declin
slowli
mani
patient
persist
viral
rna
stool
five
week
sinc
fluctuat
viral
rna
respiratori
specimen
observ
patient
fals
neg
result
inevit
specimen
detect
viral
rna
stool
specimen
may
thu
act
use
complement
monitor
treatment
current
serolog
test
wide
use
diagnosi
igm
igmigg
test
approv
emerg
use
author
eua
mani
countri
known
viral
infect
seroconvers
igm
occur
earlier
seroconvers
igg
henc
specif
igm
often
use
diagnost
marker
acut
viral
infect
result
indic
infect
patient
simultan
seroconvers
igm
igg
observ
patient
almost
patient
earlier
seroconvers
igm
igg
nearli
patient
neg
igm
across
entir
studi
period
colleagu
also
report
infect
patient
seroconvers
igg
earlier
igm
thought
might
due
low
sensit
igm
test
combin
result
togeth
appear
singl
igm
test
may
reliabl
index
auxiliari
diagnosi
infect
convalesc
igmigg
test
like
better
singl
igm
patient
nucleic
acid
test
avail
typic
symptom
neg
nucleic
acid
detect
coexist
viral
rna
specif
antibodi
report
sever
studi
observ
patient
sever
acut
respiratori
syndrom
sar
middl
eastern
respiratori
syndrom
mer
result
shown
patient
rna
coexist
antibodi
day
result
rais
concern
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
exist
protect
antibodi
sinc
one
key
role
protect
antibodi
clear
viral
infect
colleagu
report
igg
level
correl
viru
neutral
titr
studi
found
igg
peak
within
day
symptom
onset
patient
antirbd
igg
increas
fourfold
within
one
two
week
seroconvers
persist
four
week
also
found
antirbd
igm
igg
level
includ
antirbd
igm
level
present
peak
time
significantli
higher
patient
show
viral
rna
short
persist
patient
show
long
persist
data
impli
antirbd
antibodi
may
involv
clearanc
infect
would
potenti
candid
protect
antibodi
studi
need
identifi
whether
rbd
use
epitop
develop
vaccin
also
observ
length
time
symptom
onset
hospit
admiss
associ
viral
rna
clearanc
addit
seroposit
rate
anti
antirbd
igm
significantli
higher
viral
rna
long
persist
patient
base
current
evid
relationship
late
treatment
seroposit
anti
antirbd
igm
undetermin
possibl
higher
seroposit
rate
due
longer
infect
time
delay
treatment
howev
data
impli
shorter
delay
link
better
recoveri
earli
identif
earli
hospit
thu
like
effici
strategi
prevent
manag
infect
studi
limit
first
patient
number
studi
rel
small
patient
includ
studi
cours
common
weak
studi
emerg
infecti
diseas
second
sampl
viral
rna
antibodi
detect
collect
weekli
daili
basi
also
difficult
collect
sampl
exactli
oneweek
interv
patient
initi
sampl
even
miss
due
emerg
situat
infect
conclus
studi
add
import
new
inform
featur
viral
load
antibodi
dynam
clear
result
viral
rna
persist
sputum
stool
specimen
rel
long
time
mani
patient
antirbd
may
also
serv
potenti
protect
antibodi
infect
viral
persist
appear
relat
antirbd
level
earlier
treatment
intervent
also
appear
factor
viral
persist
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
studi
need
better
understand
virolog
immunolog
featur
infect
import
prevent
treatment
control
spread
diseas
contributor
sht
design
studi
full
access
data
studi
jph
ttm
wrote
report
contribut
equal
paper
sht
patient
consent
written
inform
consent
waiv
due
emerg
state
diseas
addit
data
avail
lead
author
manuscript
guarantor
affirm
manuscript
honest
accur
transpar
account
studi
report
import
aspect
studi
omit
discrep
studi
plan
relev
regist
explain
comparison
viral
load
across
differ
type
specimen
also
shown
column
repres
mean
level
antibodi
one
week
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
